BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 28, 2024
See today's BioWorld MedTech
Home
» Creatv blood test predicts response to lung cancer treatment
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Creatv blood test predicts response to lung cancer treatment
June 12, 2020
By
Annette Boyle
No Comments
Creatv Microtech Inc. has developed a simple blood test that can predict response to chemoradiation and consolidated immunotherapy in patients with non-small-cell lung cancer (NSCLC).
BioWorld MedTech
Clinical
Cancer
Diagnostics
Liquid biopsy